|
Gene: TBC1D9B |
Gene summary for TBC1D9B |
Gene summary. |
Gene information | Species | Human | Gene symbol | TBC1D9B | Gene ID | 23061 |
Gene name | TBC1 domain family member 9B | |
Gene Alias | GRAMD9B | |
Cytomap | 5q35.3 | |
Gene Type | protein-coding | GO ID | GO:0006810 | UniProtAcc | B3KM54 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
23061 | TBC1D9B | LZE4T | Human | Esophagus | ESCC | 8.73e-05 | 1.35e-01 | 0.0811 |
23061 | TBC1D9B | LZE7T | Human | Esophagus | ESCC | 1.35e-03 | 1.99e-01 | 0.0667 |
23061 | TBC1D9B | LZE8T | Human | Esophagus | ESCC | 6.49e-08 | 2.70e-01 | 0.067 |
23061 | TBC1D9B | LZE24T | Human | Esophagus | ESCC | 1.99e-13 | 4.11e-01 | 0.0596 |
23061 | TBC1D9B | LZE6T | Human | Esophagus | ESCC | 2.59e-05 | 1.84e-01 | 0.0845 |
23061 | TBC1D9B | P1T-E | Human | Esophagus | ESCC | 3.00e-07 | 4.12e-01 | 0.0875 |
23061 | TBC1D9B | P2T-E | Human | Esophagus | ESCC | 1.49e-28 | 4.24e-01 | 0.1177 |
23061 | TBC1D9B | P4T-E | Human | Esophagus | ESCC | 1.72e-16 | 2.96e-01 | 0.1323 |
23061 | TBC1D9B | P5T-E | Human | Esophagus | ESCC | 1.75e-22 | 3.71e-01 | 0.1327 |
23061 | TBC1D9B | P8T-E | Human | Esophagus | ESCC | 1.24e-15 | 1.98e-01 | 0.0889 |
23061 | TBC1D9B | P9T-E | Human | Esophagus | ESCC | 6.82e-12 | 2.77e-01 | 0.1131 |
23061 | TBC1D9B | P10T-E | Human | Esophagus | ESCC | 1.33e-20 | 3.50e-01 | 0.116 |
23061 | TBC1D9B | P11T-E | Human | Esophagus | ESCC | 2.04e-14 | 5.96e-01 | 0.1426 |
23061 | TBC1D9B | P12T-E | Human | Esophagus | ESCC | 7.70e-21 | 3.72e-01 | 0.1122 |
23061 | TBC1D9B | P15T-E | Human | Esophagus | ESCC | 1.53e-23 | 5.45e-01 | 0.1149 |
23061 | TBC1D9B | P16T-E | Human | Esophagus | ESCC | 1.74e-21 | 3.10e-01 | 0.1153 |
23061 | TBC1D9B | P17T-E | Human | Esophagus | ESCC | 6.32e-07 | 4.42e-01 | 0.1278 |
23061 | TBC1D9B | P19T-E | Human | Esophagus | ESCC | 1.32e-07 | 7.68e-01 | 0.1662 |
23061 | TBC1D9B | P20T-E | Human | Esophagus | ESCC | 2.62e-13 | 3.23e-01 | 0.1124 |
23061 | TBC1D9B | P21T-E | Human | Esophagus | ESCC | 1.46e-25 | 4.80e-01 | 0.1617 |
Page: 1 2 3 4 5 6 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004308715 | Esophagus | ESCC | regulation of GTPase activity | 183/8552 | 348/18723 | 5.34e-03 | 2.00e-02 | 183 |
GO:004308710 | Oral cavity | OSCC | regulation of GTPase activity | 165/7305 | 348/18723 | 7.94e-04 | 4.27e-03 | 165 |
GO:004308713 | Prostate | Tumor | regulation of GTPase activity | 88/3246 | 348/18723 | 1.04e-04 | 1.00e-03 | 88 |
GO:004354713 | Prostate | Tumor | positive regulation of GTPase activity | 60/3246 | 255/18723 | 6.87e-03 | 3.11e-02 | 60 |
GO:004308718 | Thyroid | PTC | regulation of GTPase activity | 148/5968 | 348/18723 | 1.63e-05 | 1.71e-04 | 148 |
GO:004354714 | Thyroid | PTC | positive regulation of GTPase activity | 103/5968 | 255/18723 | 2.38e-03 | 1.25e-02 | 103 |
GO:004308719 | Thyroid | ATC | regulation of GTPase activity | 153/6293 | 348/18723 | 3.24e-05 | 2.68e-04 | 153 |
GO:004354715 | Thyroid | ATC | positive regulation of GTPase activity | 106/6293 | 255/18723 | 4.58e-03 | 1.89e-02 | 106 |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TBC1D9B | SNV | Missense_Mutation | c.3185G>C | p.Gly1062Ala | p.G1062A | Q66K14 | protein_coding | deleterious(0.01) | probably_damaging(0.999) | TCGA-DY-A1DG-01 | Colorectum | rectum adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
TBC1D9B | SNV | Missense_Mutation | c.2606N>G | p.Ala869Gly | p.A869G | Q66K14 | protein_coding | tolerated(0.51) | benign(0.003) | TCGA-EI-6882-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
TBC1D9B | SNV | Missense_Mutation | novel | c.1177N>G | p.Phe393Val | p.F393V | Q66K14 | protein_coding | tolerated(0.07) | possibly_damaging(0.611) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
TBC1D9B | SNV | Missense_Mutation | rs145495991 | c.851N>A | p.Arg284Gln | p.R284Q | Q66K14 | protein_coding | tolerated(0.08) | probably_damaging(0.991) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
TBC1D9B | deletion | Frame_Shift_Del | c.3392delN | p.Gly1131AlafsTer78 | p.G1131Afs*78 | Q66K14 | protein_coding | TCGA-D5-6928-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |||
TBC1D9B | SNV | Missense_Mutation | rs200596277 | c.2356N>T | p.Arg786Trp | p.R786W | Q66K14 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
TBC1D9B | SNV | Missense_Mutation | rs775909263 | c.1927N>A | p.Glu643Lys | p.E643K | Q66K14 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
TBC1D9B | SNV | Missense_Mutation | c.3055N>A | p.Leu1019Ile | p.L1019I | Q66K14 | protein_coding | deleterious(0.01) | probably_damaging(0.952) | TCGA-AP-A051-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
TBC1D9B | SNV | Missense_Mutation | c.1965G>T | p.Glu655Asp | p.E655D | Q66K14 | protein_coding | tolerated(0.42) | benign(0.006) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD | |
TBC1D9B | SNV | Missense_Mutation | rs145495991 | c.851G>A | p.Arg284Gln | p.R284Q | Q66K14 | protein_coding | tolerated(0.08) | probably_damaging(0.991) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |